Vir Biotechnology, Inc. (VIR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Rhythm Pharmaceuticals, Inc.

AbCellera Biologics, Inc.

Maravai Lifesciences Holdings, Inc.

Recursion Pharmaceuticals, Inc.

CymaBay Therapeutics, Inc.

Merus NV

BioCryst Pharmaceuticals, Inc.

Arcus Biosciences, Inc.

Summit Therapeutics, Inc.

Vir Biotechnology, Inc.

Zentalis Pharmaceuticals, Inc.

Why is Vir Biotechnology, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Vir Biotechnology, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Vir Biotechnology, Inc.

90.37%

-0.16

71.07%

S&P 500

20.77%

1.56

13.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-2.13%

EBIT Growth (5y)

-17.22%

EBIT to Interest (avg)

1.09

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.84

Sales to Capital Employed (avg)

0.05

Tax Ratio

0.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

84.32%

ROCE (avg)

17.07%

ROE (avg)

12.10%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.75

EV to EBIT

-1.89

EV to EBITDA

-1.93

EV to Capital Employed

2.89

EV to Sales

12.87

PEG Ratio

Dividend Yield

ROCE (Latest)

-153.38%

ROE (Latest)

-55.98%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET SALES(HY)

Higher at USD 64.04 MM

NET PROFIT(HY)

Higher at USD -166.81 MM

-3What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 122.52% (YoY

CASH AND EQV(HY)

Lowest at USD 947.16 MM

DEBT-EQUITY RATIO (HY)

Highest at -47.08 %

Here's what is working for Vir Biotechnology, Inc.

Net Sales

At USD 64.04 MM has Grown at 315.69%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Net Sales

Higher at USD 64.04 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Net Profit

Higher at USD -166.81 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Here's what is not working for Vir Biotechnology, Inc.

Cash and Eqv

Lowest at USD 947.16 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -47.08 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 122.52% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales